Editorial HIV-related non-Hodgkin’s lymphoma (HIV-

NHL) in the era of highly active antiretroviral therapy (HAART): some still unanswered questions for clinical management Since the beginning of the AIDS epidemic the treatment of HIV-related non-Hodgkin’s lymphoma (HIV-NHL) has been a challenge. Before the introduction of highly active antiretro-viral therapy (HAART) in the management of these patients, the prognosis of HIV-NHL was poor, despite a high response rate, owing to aggressive tumor behavior, increased hemato-logical toxicity and a high rate of opportunistic infections (OIs) [1, 2]. Since the widespread use of HAART, the prog-nosis of HIV-NHL has improved, with a better tolerance to chemotherapy, a higher complete remission (CR) rate, a sig-nificant improvement of disease-free survival (DFS) and a sig-nificant reduction in the number of deaths related to HI